论文部分内容阅读
总结近几年关于三阴性乳腺癌(T N B C)辅助化疗的研究进展。以“三阴性乳腺癌、化疗”等为关键词,检索相关文献,纳入标准:(1)三阴性乳腺癌的特点;(2)T N B C化疗方案。目前对早期T N B C患者辅助化疗方案之间的疗效比较是回顾性的,分析结果显示与环磷酰胺和阿霉素联合时,紫杉醇比5-氟尿嘧啶更有效;经典的C M F方案(环磷酰胺,甲氨蝶呤和5-氟尿嘧啶)对T N B C有效;卡培他滨能增加紫杉醇联合蒽环类方案的疗效,但需进一步观察。对早期T N B C辅助治疗尚缺乏来自于前瞻性研究的数据,几个方案如含紫杉醇和蒽环类方案或经典的C M F方案可作为选择。
In recent years, the research progress of adjuvant chemotherapy for triple negative breast cancer (T N B C) was summarized. To “triple negative breast cancer, chemotherapy” as the key words, retrieve relevant literature, including the standard: (1) the characteristics of triple negative breast cancer; (2) T N B C chemotherapy. The current comparative efficacy of adjuvant chemotherapy regimens for patients with early TNBC is retrospective and the results show that paclitaxel is more effective than 5-fluorouracil when combined with cyclophosphamide and doxorubicin; the classic CMF regimen (cyclophosphamide, Methotrexate and 5-fluorouracil) on TNBC; capecitabine can increase the efficacy of paclitaxel plus anthracycline regimen, but further observation is needed. There is a lack of data from prospective studies on early T N B C adjuvant therapy and several options such as paclitaxel and anthracycline-containing regimens or classical C M F regimens are available.